Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

BACKGROUND: Two randomised, placebo-controlled trials—BENCHMRK-1 and BENCHMRK-2—investigated the efficacy and safety of raltegravir, an HIV-1 integrase strand-transfer inhibitor. We report final results of BENCHMRK-1 and BENCHMRK-2 combined at 3 years (the end of the double-blind phase) and 5 years...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Infect Dis
Main Authors: Eron, Joseph J, Cooper, David A, Steigbigel, Roy T, Clotet, Bonaventura, Gatell, Jose M, Kumar, Princy N, Rockstroh, Jurgen K, Schechter, Mauro, Markowitz, Martin, Yeni, Patrick, Loutfy, Mona R, Lazzarin, Adriano, Lennox, Jeffrey L, Strohmaier, Kim M, Wan, Hong, Barnard, Richard J O, Nguyen, Bach-Yen T, Teppler, Hedy
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6083850/
https://ncbi.nlm.nih.gov/pubmed/23664333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(13)70093-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados